Trial Profile
A Phase 1 Clinical Study of DSP-2033 (Alvocidib) in Combination with Cytarabine/Mitoxantrone or Cytarabine/Daunorubicin (7+3) in Patients with Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Alvocidib (Primary) ; Cytarabine; Daunorubicin; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Sumitomo Dainippon Pharma; Sumitomo Pharma
- 01 Dec 2022 Results assessing the safety and tolerability of alvocidib administered in combination with either cytarabine and mitoxantrone for acute myeloid leukemia cytarabine/daunorubicin for newly diagnosed acute myeloid leukemia, published in the Cancer Science.
- 18 Dec 2020 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology